Clinical standard research of multicenter clinical control study of noncytotoxic drug- gastric carcinoma D2 radical correction- Capecitabine combined therapy in gastric carcinoma.

Trial Profile

Clinical standard research of multicenter clinical control study of noncytotoxic drug- gastric carcinoma D2 radical correction- Capecitabine combined therapy in gastric carcinoma.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 May 2012

At a glance

  • Drugs Capecitabine (Primary) ; Celecoxib; Lanreotide
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date 31 May 2013 added as reported by Chinese Clinical Trial Register.
    • 14 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top